Related Experiment Video

Updated: Jul 9, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

Liver X receptor and farnesoid X receptor as therapeutic targets

Daniel J Rader1

  • 1University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6160, USA. rader@mail.med.upenn.edu

The American Journal of Cardiology
|December 6, 2007
PubMed

Insights

New therapies targeting dyslipidemia are needed. Liver X receptor (LXR) and farnesoid X receptor (FXR) offer distinct therapeutic strategies for cholesterol and triglyceride management.

Area of Science:

  • Pharmacology and Molecular Biology
  • Lipid Metabolism Research
  • Cardiovascular Disease Therapeutics

Background:

  • Existing dyslipidemia therapies have limitations, necessitating novel treatment strategies.
  • Liver X receptor (LXR) and farnesoid X receptor (FXR) are key nuclear receptors involved in lipid homeostasis.
  • Dyslipidemia, characterized by abnormal lipid levels, remains a significant risk factor for cardiovascular diseases.

Purpose of the Study:

  • To explore the therapeutic potential of Liver X receptor (LXR) and farnesoid X receptor (FXR) as targets for novel dyslipidemia treatments.
  • To evaluate the role of LXR agonists in cholesterol regulation and atherosclerosis.
  • To investigate the utility of FXR modulators in managing triglycerides and other lipid parameters.

Main Methods:

  • Preclinical studies involving LXR agonists to assess effects on cholesterol and hepatic fat.
  • Analysis of FXR agonist properties for triglyceride reduction in dyslipidemia models.
  • Exploration of FXR antagonist or modulator potential for low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) metabolism.

Main Results:

  • LXR agonists demonstrate potential in reducing atherosclerosis in animal models, despite some preclinical increases in hepatic fat and LDL cholesterol.
  • FXR agonists show promise for triglyceride-lowering effects, beneficial for specific dyslipidemias.
  • FXR modulators may offer avenues for lowering LDL cholesterol and influencing HDL metabolism.

Conclusions:

  • LXR represents a significant target for developing new therapies aimed at cholesterol reduction and atherosclerosis prevention.
  • FXR presents a complex yet promising target for addressing triglyceride disorders and potentially modulating LDL and HDL cholesterol.
  • Targeting both LXR and FXR pathways offers distinct and potentially complementary approaches to managing complex dyslipidemias.

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Signal Transduction: Overview01:26

Signal Transduction: Overview

Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...